Lauxera has closed an oversubscribed €520 million fund to help European medtech companies expand in the United States, strengthening its position as a specialist investor in healthcare technologies. The fund is designed to support companies that already have strong products in Europe but need capital, operational support and market access to scale across the Atlantic.

The move reflects a broader push to bridge the gap between Europe’s medtech innovation base and the much larger U.S. healthcare market, where regulatory, commercial and reimbursement hurdles can be difficult for foreign companies to navigate. By backing growth-stage medtech firms, Lauxera aims to accelerate their international expansion and help them build a stronger presence in the world’s largest healthcare market.

The article does not provide additional details beyond the fund size and strategic objective, but the oversubscription signals investor confidence in Lauxera’s thesis and in the growth potential of European medtech companies seeking U.S. expansion.

L’article Lauxera sursouscrit un fonds de 520 millions pour accélérer les medtech européennes aux États-Unis est apparu en premier sur Maddyness - Le média pour comprendre l'économie de demain.